News Release

March 04, 2022

ReAlta Life Sciences Announces Poster Presentation at the American Academy of Neurology 2022 Annual Meeting

Presenting first-in-human trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product candidate

NORFOLK, Va., March 4th, 2022 –(BUSINESS WIRE)–ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting clinical data from its first-in-human trial in healthy volunteers on RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate. RLS-0071 is being developed as a treatment for hypoxic ischemic encephalopathy and other rare diseases. The data will be presented at the American Academy of Neurology 2022 Annual Meeting to be held in person in Seattle on April 2 to 6, 2022, and virtually on April 24 to 26, 2022.

Details of the presentation:

Title: RLS-0071-101 a study in healthy human volunteers demonstrates safety, complement and inflammatory effector target engagement activity of this novel peptide

Authors: Kenji Cunnion, Parvathi Kumar, Neel Krishna, Ulrich Thienel, L. Matthew Frank, ReAlta Life Sciences, Children’s Specialty Group

Presentation: Poster #002; Neighborhood 7

Session: P12: Neurocritical Care: COVID-19, TBI and Other Topics 2

Date/ Time: Tuesday, April 5, 5:30 – 6:30 p.m. PDT

About ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a clinical-stage biotech company dedicated to harnessing the power of the immune system to address life threatening rare diseases. The Company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia. For more information, please visit



Media Contact:
Robert Flamm, Ph.D.
Burns McClellan

Investor contact:
Eric Ando
Burns McClellan


Feb 16, 2021

ReAlta Life Sciences Doses First Subject In Phase 1 Healthy Volunteers Study...

Norfolk, VA, February 16, 2021 – ReAlta Life Sciences, Inc. (“ReAlta”), a company addressing life-threatening diseases through harnessing the power...

Read More
Dec 03, 2020

ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 For The...

Norfolk, VA, December 3, 2020 — ReAlta Life Sciences, Inc., today announced that the European Medicines Agency (EMA) has granted Orphan...

Read More
Nov 19, 2020

ReAlta Life Sciences Featured In Norfolk Innovation Corridor, Launch Of New Technology...

Norfolk, VA, November 19, 2020 — Norfolk, Virginia, known globally for its expertise in resilience and strong entrepreneurship ecosystem, is...

Read More